Stocks TelegraphStocks Telegraph
Stock Ideas

VVOS Financial Statements and Analysis

NASDAQ : VVOS

Vivos Therapeutics

$0.20
-0.0289-12.85%
At Close 4:00 PM
$0.19
−0.0066-3.37%
After-Market 08:30 PM
68.47
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
revenue5.153M5.141M6.783M3.82M3.016M
cost of revenue2.20M2.536M2.846M1.71M1.507M
gross profit2.953M2.605M3.937M2.11M1.509M
gross profit ratio0.5730.5070.580.5520.50
research and development expenses00000
general and administrative expenses7.113M8.971M7.884M6.409M4.892M
selling and marketing expenses155.00K249.00K403.00K260.00K358.00K
selling general and administrative expenses7.268M9.22M8.287M6.669M5.25M
other expenses510.00K0000
operating expenses7.778M9.22M8.287M6.669M5.25M
cost and expenses9.978M11.756M11.133M8.379M6.757M
interest income00000
interest expense1.10M0000
depreciation and amortization0454.00K384.00K306.00K177.00K
ebitda-4.423M-7.297M-5.016M-4.707M-3.564M
ebitda ratio-0.858-1.419-0.739-1.232-1.182
operating income-4.825M-6.615M-4.35M-4.865M-3.741M
operating income ratio-0.936-1.287-0.641-1.274-1.24
total other income expenses net-698.00K-1.136M-1.05M-454.00K54.00K
income before tax-5.523M-7.751M-5.40M-5.013M-3.864M
income before tax ratio-1.072-1.508-0.796-1.312-1.281
income tax expense00000
net income-5.481M-7.751M-5.40M-5.013M-3.864M
net income ratio-1.064-1.508-0.796-1.312-1.281
eps-0.31-0.52-0.49-0.55-0.45
eps diluted-0.31-0.52-0.49-0.55-0.45
weighted average shs out17.682M14.634M10.964M9.087M8.595M
weighted average shs out dil17.682M14.634M10.964M9.087M8.595M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
cash and cash equivalents1.774M2.11M3.087M4.402M2.342M
short term investments00000
cash and short term investments1.774M2.11M3.087M4.402M2.342M
net receivables1.438M1.769M2.134M1.633M718.00K
inventory00000
other current assets1.001M940.00K565.00K695.00K547.00K
total current assets4.213M4.819M5.786M6.73M3.607M
property plant equipment net7.449M7.559M9.025M8.373M4.259M
goodwill8.572M8.572M8.45M8.45M2.843M
intangible assets3.638M3.839M2.172M2.225M358.00K
goodwill and intangible assets12.21M12.411M10.622M10.675M3.201M
long term investments00000
tax assets00000
other non current assets272.00K254.00K211.00K255.00K215.00K
total non current assets19.931M20.224M19.858M19.303M7.675M
other assets00000
total assets24.144M25.043M25.644M26.033M11.282M
account payables2.946M1.996M2.103M1.763M1.206M
short term debt8.618M8.099M1.128M866.00K467.00K
tax payables00000
deferred revenue0495.00K0480.00K572.00K
other current liabilities8.825M7.347M4.206M3.317M2.456M
total current liabilities20.389M17.937M7.437M6.426M4.701M
long term debt3.521M4.169M2.991M10.715M932.00K
deferred revenue non current0005.00K22.00K
deferred tax liabilities non current00000
other non current liabilities4.22M4.204M12.684M4.304M1.22M
total non current liabilities7.741M8.373M15.675M15.024M2.174M
other liabilities00000
capital lease obligations04.551M3.78M3.664M1.399M
total liabilities28.13M26.31M23.112M21.45M6.875M
preferred stock00000
common stock1.00K1.00K1.00K00
retained earnings-138.52M-133.039M-118.464M-113.064M-108.051M
accumulated other comprehensive income loss00000
other total stockholders equity134.704M131.90M120.995M117.647M112.458M
total stockholders equity-3.815M-1.138M2.532M4.583M4.407M
total equity-3.986M-1.267M2.532M4.583M4.407M
total liabilities and stockholders equity24.144M25.043M25.644M26.033M11.282M
minority interest-171.00K-129.00K000
total investments00000
total debt12.139M12.268M4.119M11.581M1.399M
net debt10.365M10.158M1.032M7.179M-943.00K
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
deferred income tax00000
stock based compensation50.00K151.00K55.00K242.00K317.00K
change in working capital1.882M482.00K-445.00K871.00K-426.00K
accounts receivables331.00K-188.00K-501.00K19.00K-288.00K
inventory00000
accounts payables950.00K318.00K340.00K499.00K109.00K
other working capital601.00K352.00K-106.00K353.00K-247.00K
other non cash items-68.00K654.00K1.244M100.00K0
net cash provided by operating activities-3.148M-6.01M-4.161M-3.494M-3.796M
investments in property plant and equipment18.00K-18.00K893.00K-771.00K-122.00K
acquisitions net005.135M-5.135M0
purchases of investments00000
sales maturities of investments00000
other investing activites-434.00K0-5.945M00
net cash used for investing activites-416.00K-18.00K83.00K-5.906M-122.00K
debt repayment797.00K980.00K09.642M0
common stock issued2.431M5.129M957.00K1.818M0
common stock repurchased00000
dividends paid00000
other financing activites002.763M00
net cash used provided by financing activities3.228M6.109M2.763M11.46M0
effect of forex changes on cash00000
net change in cash-336.00K81.00K-1.315M2.06M-3.918M
cash at end of period1.774M2.11M3.087M4.402M2.342M
cash at beginning of period2.11M2.029M4.402M2.342M6.26M
operating cashflow-3.148M-6.01M-4.161M-3.494M-3.796M
capital expenditure18.00K-18.00K893.00K-771.00K-122.00K
free cash flow-3.13M-6.01M-3.268M-4.265M-3.796M
Graph

Frequently Asked Questions

How did Vivos Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, VVOS generated $5.15M in revenue last quarter, while its costs came in at $2.20M.
Last quarter, how much Gross Profit did Vivos Therapeutics, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Vivos Therapeutics, Inc. reported a $2.95M Gross Profit for the quarter ended Jun 30, 2026.
Have VVOS's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. VVOS incurred $7.78M worth of Operating Expenses, while it generated -$4.83M worth of Operating Income.
How much Net Income has VVOS posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Vivos Therapeutics, Inc., the company generated -$5.48M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Vivos Therapeutics, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Vivos Therapeutics, Inc. as of the end of the last quarter was $1.77M.
What are VVOS's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, VVOS had Total Net Receivables of $1.44M.
In terms of Total Assets and Current Assets, where did Vivos Therapeutics, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of VVOS were $4.21M, while the Total Assets stand at $24.14M.
As of the last quarter, how much Total Debt did Vivos Therapeutics, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of VVOS's debt was $12.14M at the end of the last quarter.
What were VVOS's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, VVOS reported total liabilities of $28.13M.
How much did VVOS's Working Capital change over the last quarter?
Working Capital Change for VVOS was $1.88M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
VVOS generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. VVOS generated -$3.15M of Cash from Operating Activities during its recently reported quarter.
What was VVOS's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. VVOS reported a -$336.00K Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph